Compositions and methods relating to the inhibition of casomorphin and gluteomorphin
CA 2385864 A1 · Owner: Klaire Laboratories, Inc. · Inventors: Wilkinson, Randall Eugene; Houston, Devin B.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Compositions and methods able to reduce opioid-related symptoms in a human patient of an exorphin selected from the group consisting of a gluteomorphin and a caseomorphin, comprising a physiologically effective amount of a purified casomorphin inhibitor selected from the group consisting of a casomorphinase and a casomorphin ligand a physiologically effective amount of a purified gluteomorphin inhibitor selected from the group consisting of a gluteomorphinase and a gluteomorphin ligand and at least one of the group , consisting of a physiologically acceptable carrier adjuvant, excipient, buffer and diluent. In some embodiments the compositions and methods further , comprise a …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 27, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended September 27, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 27, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.